Charles River Laboratories International (NYSE:CRL) EVP Sells $599,710.68 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 2,039 shares of Charles River Laboratories International stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total transaction of $599,710.68. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,413,834.84. This trade represents a 29.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

Shares of CRL opened at $295.23 on Friday. The company’s 50-day moving average is $234.99 and its 200-day moving average is $193.86. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm has a market capitalization of $14.09 billion, a PE ratio of -60.87, a PEG ratio of 3.06 and a beta of 1.38. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $299.32.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CRL. Invesco Ltd. lifted its holdings in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Victory Capital Management Inc. increased its position in Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. increased its position in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares in the last quarter. Amundi lifted its stake in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares during the last quarter. Finally, Norges Bank bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $96,765,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International News Roundup

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River is collaborating with Medigen Vaccine Biologics to advance vaccine-development programs using next-generation sequencing. The partnership could expand CRL’s support for biologics and vaccine customers, although financial terms were not disclosed. Charles River Labs and Medigen Vaccine collaboration
• Positive Sentiment: Analysts highlight DSA’s return to organic growth, stronger bookings, and new testing capabilities as key drivers behind CRL’s approximately 88.6% one-year advance. These trends support the company’s strategy of broadening its role in drug-development services. Charles River rally drivers
• Neutral Sentiment: Options-market activity suggests traders are positioning for a potentially significant move in CRL shares, but the activity does not establish whether the anticipated move will be upward or downward. CRL options activity
• Negative Sentiment: Zacks cautions that the recent 33.3% monthly surge has raised the bar for execution. Margin pressure and a premium valuation may constrain upside unless bookings and guidance continue to improve. CRL valuation and rally outlook
• Negative Sentiment: Director Nancy Andrews sold 573 shares for approximately $163,443, reducing her direct holdings by 28.5%. The transaction is modest but adds to investor focus on insider selling after the stock’s rally. Nancy Andrews insider sale
• Negative Sentiment: EVP Shannon M. Parisotto sold 2,039 shares for approximately $599,711, reducing direct ownership by 29.8%; the sale was made under a pre-arranged Rule 10b5-1 trading plan, which lessens its signaling value. Shannon Parisotto insider sale

Analysts Set New Price Targets

CRL has been the topic of a number of analyst reports. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Mizuho set a $264.00 target price on Charles River Laboratories International in a research report on Monday, August 10th. Royal Bank Of Canada increased their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Finally, Robert W. Baird set a $291.00 price target on Charles River Laboratories International in a research note on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.65.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.